Early Administration of Romidepsin and 3BNC117 in Treatment-naïve HIV Patients Starting ART

The study will be conducted among ART naïve HIV-1-infected patients. Subjects will continue ART while receiving LRA romidepsin and/or bNAb 3BNC117.

Early Administration of Latency Reversing Therapy and Broadly Neutralizing Antibodies to Limit the Establishment of the HIV-1 Reservoir During Initiation of Antiretroviral Treatment - a Randomized Controlled Trial

To evaluate the effect of early viral reactivation by latency reversing agents (LRA) and/or administration of potent broadly neutralizing antibodies (bNAb) on the size of the latent HIV-1 reservoir in treatment naïve HIV-1 patients initiating antiretroviral therapy (ART)

Early Administration of Romidepsin and 3BNC117 in Treatment-naïve HIV Patients Starting ART

Recruitment

Summary

Participation Requirements

Description

Tracking Information